8-K 1 cli8k100504.txt FORM 8-K CURRENT REPORT ============================================================================ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________ FORM 8-K _________________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 5, 2004 CARRINGTON LABORATORIES, INC. ------------------------------------------------------ (Exact name of Registrant as specified in its charter) Texas 0-11997 75-1435663 ---------------------------- ---------- ---------------- (State or other jurisdiction Commission (I.R.S. Employer of incorporation or organization) File Number Identification No.) 2001 Walnut Hill Lane Irving, Texas 75038 ---------------------------------------- ---------- (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code: (972) 518-1300 ---------------------------------------------------- (Former name, former address and former fiscal year, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below): [ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) [ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) [ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) [ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) ============================================================================ Item 8.01. Other Events. On October 5, 2004, Carrington Laboratories, Inc. (the "Registrant") issued a press release announcing the receipt by its wholly-owned subsidiary, DelSite Biotechnologies, Inc., of a grant from the National Institute of Allergy and Infectious Diseases to develop a nasal powder vaccine against the flu strain commonly known as bird flu. A copy of the Registrant's press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. Item 9.01. Financial Statements and Exhibits. c. Exhibits 99.1 Press Release of the Company dated October 5, 2004. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. CARRINGTON LABORATORIES, INC. Date: October 7, 2004 By: /s/ Carlton E. Turner ------------------------------------- Carlton E. Turner President and CEO EXHIBIT INDEX Exhibit Number Description ------ ----------- 99.1 Press Release dated October 5, 2004.